Immix Biopharma Receives Tepid Wall Street Reception in IPO Debut
Photo by National Cancer Institute on Unsplash

Immix Biopharma Receives Tepid Wall Street Reception in IPO Debut

Immix Biopharma Inc., a Santa Monica-based biotechnology company, got slammed in its trading debut this week, losing 27% of its value in its first day of trading on Nasdaq.

On Friday, the tiny biotech’s stock closed at $4 a share, a recovery of about 9% from its previous opening day’s close.


The nine-year-old company, which is known for its tissue-specific therapeutics that aims to help doctors rely less on traditional chemotherapy, was cofounded by Ilya Rachman, a physician at the world renowned Cedars-Sinai Medical Center in Los Angeles.

Immix raised $21 million in its IPO.

Proceeds from the IPO will be used to fund clinical trials for several of its cancer therapeutics that target tumors, colorectal cancer and soft tissue sarcoma. It’s planning several trials of its therapies, or medical treatments, in 2022.

Overall, the company is focusing its research on soft-tissue sarcomas, which are a group of cancers found in blood vessels, fat cells and the lining of joints.

Gabriel Morris, chief financial officer of Immix, did not return phone calls seeking comment on his company’s initial public offering, or IPO, and its tepid reception that it received on Wall Street.

In an email, Morris wrote Friday that the company is in a regulatory and legal “quiet period” which prohibits the company from making any public statements for another 25 days.

In 2020, the early stage growth company with a market capitalization of $26.4 million, reported a loss of $1.1 million. It also reported a loss of $1.6 million in its first nine months of 2021.

In filings with the U.S. Securities and Exchange Commission, Immix says that its competitors include biotech firms like Kymera Therapeutics Inc.; Morphic Holding Inc.; RAPT Therapeutics Inc.; Arena Pharmaceuticals Inc.; Landos Biopharma Inc.; and, Seres Therapeutics Inc.

dot.LA reporter Keerthi Vedantam contributed to this post.

Subscribe to our newsletter to catch every headline.

Cadence

In this episode of LA Venture, Julie Wroblewski talks about starting Magnify Ventures and helping modern families.

Wroblewski worked with Melinda French Gates to start Pivotal Ventures. For Wroblewski, it was her dream job as she got to lead venture capital investment strategy for five years. One of the focus areas at Pivotal was around caregiving innovation and American family homes.

Read more Show less
Minnie Ingersoll
Minnie Ingersoll is a partner at TenOneTen and host of the LA Venture podcast. Prior to TenOneTen, Minnie was the COO and co-founder of $100M+ Shift.com, an online marketplace for used cars. Minnie started her career as an early product manager at Google. Minnie studied Computer Science at Stanford and has an MBA from HBS. She recently moved back to L.A. after 20+ years in the Bay Area and is excited to be a part of the growing tech ecosystem of Southern California. In her space time, Minnie surfs baby waves and raises baby people.

Pejman Nozad, a founding managing partner at Pear VC, joins this episode of LA Venture to discuss Pear VC's current initiatives, including its accelerator and fellowships. He's seen as one of the most successful angel investors in the area, and for good reason: he has made more than 300 investments in his lifetime.

Read more Show less
Minnie Ingersoll
Minnie Ingersoll is a partner at TenOneTen and host of the LA Venture podcast. Prior to TenOneTen, Minnie was the COO and co-founder of $100M+ Shift.com, an online marketplace for used cars. Minnie started her career as an early product manager at Google. Minnie studied Computer Science at Stanford and has an MBA from HBS. She recently moved back to L.A. after 20+ years in the Bay Area and is excited to be a part of the growing tech ecosystem of Southern California. In her space time, Minnie surfs baby waves and raises baby people.
RELATEDTRENDING
LA TECH JOBS
interchangeLA